A recent study indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who stop conventional diet and exercise regimens.
Published data in a leading health publication points out that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month after stopping.
"People using these treatments should be aware of the risk of fast rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a return to original weight within about one and a half years.
Analyzing Treatments
The analysis, which reviewed dozens of trials involving thousands of participants, compared the outcomes of these new drugs with older methods.
Researchers point out that people who shed pounds through dieting generally have a less rapid weight regain—around 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Experts believe the way of the drugs is key to understanding the heightened weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls hunger.
"Sustained high doses of the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in hunger is no longer kept in check, making binge eating far more likely."
A Lifelong Disease?
Health authorities advise the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, due to the likelihood of relapse, the treatment is often long-term.
This perspective is echoed by drug manufacturers, who state that the findings "underscore the long-term character of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the medication describe a intense resurgence of cravings.
"I experienced a trigger that goes on and I was suddenly starving," said one woman.
The struggle is worsened if patients have not established lasting dietary or behavioural modifications during treatment.
Growing Adoption
Recent estimates show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is greater among women than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while the jabs are powerful agents for shedding pounds, they are not a standalone cure and long-term success likely depends on ongoing lifestyle changes.
